A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

开始日期2020-05-28

申办/合作机构-

NCT04195906 / Completed临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis

The primary objectives are to assess the efficacy, safety, and tolerability of SNF472 compared to placebo when added to background care for the treatment of calciphylaxis (CUA).

开始日期2020-02-12

申办/合作机构

Sanifit Therapeutics SA

EUCTR2016-002834-59-ES / Not yet recruiting临床2期

A double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on progression of cardiovascular calcification on top of standard of care in end-stage-renal-disease (ESRD) patients on haemodialysis (HD)

开始日期2016-11-16

申办/合作机构-

100 项与植酸钠相关的临床结果

登录后查看更多信息

100 项与植酸钠相关的转化医学

登录后查看更多信息

100 项与植酸钠相关的专利（医药）

登录后查看更多信息

137

项与植酸钠相关的文献（医药）

2024-10-01·Journal of Colloid and Interface Science

Effect of cross-linking density on the rheological behavior of ultra-soft chitosan microgels at the oil–water interface

Article

作者: Zhen, Shiyu ; Kong, Songmei ; Yang, Nan ; Li, Zhenzhen ; Sun, Fusheng ; Ma, Xuxi

In this paper, microgels with uniform particle size were prepared by physically cross-linking the hydrophobically modified chitosan (h-CS) with sodium phytate (SP). The effects of cross-linking density on the interfacial adsorption kinetics, viscoelasticity, stress relaxation, and micorheological properties of the hydrophobically modified chitosan microgels (h-CSMs) at the oil-water interface were extensively investigated by the dilatational rheology, compressional rheology, and particle tracing microrheology. The results were correlated with the particle size, morphology, and elasticity of the microgels characterized by dynamic light scattering and atomic force microscopy. It was found that with the increase of cross-linking density, the h-CSMs changed from a polymer-like state to ultra-soft fussy spheres with higher elastic modulus. The compression isotherms demonstrated multi-stage increase caused by the interaction between the shells and that between the cores of the microgels successively. As the increase of cross-linking density, the h-CSMs diffused slower to the oil-water interface, but demonstrating faster permeation adsorption and rearrangement at the oil-water interface, finally forming interfacial layers of higher viscoelastic modulus due to the core-core interaction. Both the initial tension relaxation and the microgel rearrangement after interface expansion became faster as the microgel elasticity increased. The interfacial microrheology demonstrated dynamic caging effect caused by neighboring microgels. This article provides a more comprehensive understanding of the behaviors of polysaccharide microgels at the oil-water interface.

2024-10-01·International Journal of Toxicology

Safety Assessment of Polyol Phosphates as Used in Cosmetics

Review

作者: Klaassen, Curtis D. ; Slaga, Thomas J. ; Shank, Ronald C. ; Fiume, Monice ; Bergfeld, Wilma F. ; Johnson, Wilbur ; Heldreth, Bart ; Marks, James G. ; Liebler, Daniel C. ; Snyder, Paul W. ; Belsito, Donald V. ; Hill, Ronald A.

The Expert Panel for Cosmetic Ingredient Safety (Panel) reviewed the safety of 10 polyol phosphates. Some of the possible functions in cosmetics that are reported for this ingredient group are chelating agents, oral care agents, and skin conditioning agents. The Panel reviewed relevant data relating to the safety of these ingredients under the intended conditions of use in cosmetic formulations, and concluded that Sodium Phytate, Phytic Acid, Phytin, and Trisodium Inositol Triphosphate are safe in cosmetics in the present practices of use and concentration described in the safety assessment. The Panel also concluded that the data are insufficient to determine the safety of the following 6 ingredients as used in cosmetics: Disodium Glucose Phosphate, Manganese Fructose Diphosphate, Sodium Mannose Phosphate, Trisodium Fructose Diphosphate, Xylityl Phosphate, and Zinc Fructose Diphosphate.

2024-09-01·eClinicalMedicine

Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension

Article

作者: Nigwekar, Sagar U. ; Brandenburg, Vincent ; Aronoff, George R ; Serena, Thomas E. ; Moe, Sharon M ; Perelló, Joan ; Aronoff, George R. ; Serena, Thomas E ; Carroll, Kevin J ; Chatoth, Dinesh K. ; Chatoth, Dinesh K ; Gold, Alex ; Keller, Laurence H. ; Keller, Laurence H ; Nigwekar, Sagar U ; Alperovich, Gabriela ; Hymes, Jeffrey L. ; Sinha, Smeeta ; Carroll, Kevin J. ; Hymes, Jeffrey L ; Chertow, Glenn M. ; Moe, Sharon M. ; Chertow, Glenn M ; Gould, Lisa J. ; Gould, Lisa J

BackgroundIn the CALCIPHYX trial, we investigated hexasodium fytate, an inhibitor of vascular calcification, for the treatment of calcific uraemic arteriolopathy (calciphylaxis), a rare condition characterised by painful, non-healing skin lesions.MethodsIn this international, phase 3, randomised, double-blind, placebo-controlled trial, adults with an ulcerated calciphylaxis lesion and pain visual analogue scale (VAS) score ≥50/100 were randomised 1:1 to hexasodium fytate 7 mg/kg or placebo intravenously during maintenance haemodialysis. Primary efficacy outcomes were an 8-item modification of the Bates-Jensen Wound Assessment Tool (BWAT-CUA) and Pain VAS in the intention-to-treat population. ClinicalTrials.gov number: NCT04195906.FindingsOverall, 34/37 patients randomised to hexasodium fytate and 26/34 patients randomised to placebo completed the 12-week randomised treatment period. At Week 12, both groups (hexasodium fytate versus placebo) showed similar improvements in BWAT-CUA (mean [standard deviation (SD)], -5.3 [5.2] versus -6.0 [6.2]; least squares mean difference, 0.3 [96% confidence interval (CI): -2.5, 3.0]; p = 0.88) and Pain VAS (mean [SD], -19.5 [26.9] versus -32.2 [38.5]; least squares mean difference, 11.5 [96% CI: -4.8, 27.8]; p = 0.15). One patient randomised to placebo briefly received hexasodium fytate in error. Serious adverse events through Week 12 included: calciphylaxis-related events leading to hospitalisation (2/38 [5%] versus 11/33 [33%]) and death (1/38 [3%] versus 5/33 [15%]). During the subsequent 12 weeks of open-label hexasodium fytate and 4 weeks of follow-up, there were no additional calciphylaxis-related events leading to hospitalisation. Over the course of the entire trial, deaths were 2/38 [5%] for the hexasodium fytate group and 7/33 [21%] for the placebo group.InterpretationIn patients with calciphylaxis, BWAT-CUA and Pain VAS improved similarly in hexasodium fytate- and placebo-treated patients; over the course of the entire trial, there were fewer deaths and calciphylaxis-related events leading to hospitalisation in the hexasodium fytate group.FundingFunded by Sanifit, a CSL Vifor company.

项与植酸钠相关的新闻（医药）

2023-03-29

·Endpoints

Q&A: Newly-minted CSL chief executive Paul McKenzie and chief medical officer Bill Mezzanotte

Paul McKenzie took over as CEO of Australian pharma giant CSL this month, following in the footsteps of long-time CSL vet Paul Perreault. With an eye on mRNA, and quickly commercializing its new, $3.5 million-per-shot gene therapy for hemophilia B, McKenzie and chief medical officer Bill Mezzanotte answered some questions from Endpoints News this afternoon about where McKenzie is going to take the company and what advances may be coming to market from CSL’s pipeline. Below is a lightly edited transcript. Endpoints: You took over this month as CEO from long-time CSL veteran Paul Perreault — in what ways are you going to move the company into new areas, and what have you learned from what Mr. Perreault as he led CSL over the last decade? McKenzie : It’s a real privilege to be able to be given this opportunity to work with this fantastic management team. That dedication and promise we have to patients and from my first interaction with CSL, that was critically important. From Paul, that passion, he knows some of the patients in hemophilia by first name, and that’s something that won’t change. What I also learned was that as the organization grows larger, is to really focus. It’s easy to do lots of things, and harder to do a few things very well. As a management team we spent a lot of time, as we came and dealt with Covid, on focus and making sure everyone in the organization understands where we need to be and where we need to put our efforts. That doesn’t mean ideas aren’t welcome, but not every idea can be prosecuted on a given day. Right now we’re focused on our journey to sustainable and profitable growth and that requires us to reestablish firmly our leadership in the plasma market, requires us to continue to drive our R&D portfolio and interest and desire in differentiating. It’s not like we have a big change in strategy. As a management team we have great continuity; we’re firmly rooted in our CSL 2030 strategy, and a year or two out, we’ll start working on our 2035 and 2040. Endpoints : You recently won approval for the world’s first gene therapy for hemophilia B — Hemgenix. How competitive is this space going to be in the near term? And when you look at the data Pfizer released in December, is there a concern that this market isn’t big enough for two $3 million-plus gene therapies? McKenzie : What we know is our data and our data look fantastic. We’re an AAV5 platform out of the partnership with uniQure, and continue to see good durability. We set a high bar. AAV5 is unique in our ability to dose even though people may have antibodies prior to AAV5, which is very differentiated from the AAV8 or AAV9 historic platforms. We’re very bullish in our ability to make a real difference for patients that want to have a solution other than the standard of care, [CSL’s] Idelvion. Mezzanotte : Every area we’re in has healthy competition and Pfizer has great scientists, but we’re quite happy with the molecule we have, the data we’ve generated and of course the commercial experience we have. Endpoints : Can you say anything about the uptake or interest in Hemgenix since its approval? Mezzanotte : There’s substantial interest and we’ve already had physicians in the US write prescriptions. However, this is gene therapy, not a pill, so there’s work with the payers to ensure reimbursement and that the sites are going through the process right so the dose is administered correctly. Obviously you don’t want to mess up the dosage of an expensive therapy. We expect very soon to be able to report that patients have been dosed. But I can tell you around the world there’s a lot of interest. I was just in Japan, and I was interviewed there about Hemgenix. Endpoints : How have payers reacted to the list price of $3.5 million, and has it been a barrier to access? McKenzie : In the US, the ICER report really looked at the overall burden of disease and showed this to be a very effective treatment. In the US, we’ve had good rapport, and good discussions relative to reimbursement. Not a lot of differentiation of the model. More of, “Hey, is it the right patient, can they be successful?” And in the other parts of the world, there’ll be different business models that likely will have to be implemented to ensure this is a durable product for patients. We’ll listen and be attentive to what the different countries we need, but I think in the US, the discussions have been in the right direction and firmly based on the ICER data. Mezzanotte : I was just at an R&D meeting and the general sentiment was we want to figure out a way to pay for these therapies. These are the future. I think they’re playing with a variety of models on how to do that, but I sat in on some meetings with payers and there really isn’t pushback on the drug, and there are questions on pricing, but we’re having good discussions and because of our history in hemophilia, we have relationships with them. Endpoints : Looking at your Phase III pipeline, what assets are you most excited about and going to be seeing readouts in the nearest future? McKenzie : I shook up my colleagues by saying at our investor day that we had a number in there that I thought could be standard of care in the future if they have the data we hope. Obviously the number one coming out is garadacimab, an anti-FXIIa monoclonal antibody, which showed great Phase III efficacy and tolerability data, and we’ll be filing that this year as a potential treatment of hereditary angioedema (HAE) by subcutaneous administration. We’re still excited about CSL112, our apoA-I product for patients who have suffered a heart attack; those data will be coming out next year. And one we haven’t talked about as much but I remain excited about, and we’ll be seeing data at some point this year or maybe early next, is [CSL964,] an alpha-1 antitrypsin, which is being tested in both prevention and treatment of graft versus host disease. From the Vifor side, very soon, by the first half of this year we should have data on SNF472, which actually came from a little company in Spain. This is a quite impactful drug if it works. Mezzanotte : On flu, aQIVc (Adjuvanted Cell Culture Influenza Vaccine) takes the best of our cell technology, Flucelvax, with our adjuvant [MF59] to bring the next standard of care in flu. That will start in Phase III clinical trials in this Northern Hemisphere campaign and we really think that will be the next bar that people will compare to non-egg-based adjuvanted product offering, which continues our differentiation journey. And then beyond that is the differentiation built around self-amplifying mRNA.

临床3期高管变更疫苗临床结果基因疗法

2022-11-02

·PRNewswire

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 /PRNewswire/ -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health. CSL revealed progress and plans in advancing assets that have the potential to disrupt current standards of care in its areas of focus (immunology, haematology, respiratory, cardiovascular and metabolic, transplant, nephrology, vaccines) using its strategic scientific platforms (plasma protein technology, recombinant technology, cell and gene therapy, and sa-mRNA, adjuvanted, cell-based and egg-based vaccines). Among the highlights presented were the following: Late-Stage Development Includes Disruptive Innovation and New Additions to the CSL Portfolio Etranacogene dezaparvovec (also known as CSL222), an investigational gene therapy for the treatment of adults with haemophilia B has been accepted for priority review by the United States (US) Food and Drug Administration (FDA) and standard review by the European Medicines Agency (EMA). If approved, etranacogene dezaparvovec would be the first-ever gene therapy treatment option for the haemophilia B community. The regulatory filings are supported by results from the pivotal HOPE-B trial, the largest gene therapy trial in haemophilia B to date. The multi-year clinical development program for etranacogene dezaparvovec was led by uniQure (Nasdaq: QURE) and sponsorship of the clinical trials has transitioned to CSL after acquiring global rights to commercialize the investigational treatment. Top-line Phase III results for garadacimab (CSL312, anti-FXIIa), an investigational first-in-class monoclonal antibody being developed as a long-term preventive treatment for patients with hereditary angioedema, demonstrated that the study met its primary and secondary efficacy objectives and showed favourable safety and tolerability. CSL aims to begin filing for approval with global regulatory authorities next calendar year. Garadacimab was discovered and optimised by scientists at CSL's Bio21–based Research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. CSL Vifor brings a leading portfolio of therapies in nephrology, dialysis and iron deficiency. New late-stage assets to the pipeline include Sparsentan for IgA nephropathy and focal segmental glomerulosclerosis (FSGS) and SNF472 for calciphylaxis and calcific uremic arteriolopathy (CUA). R&D Portfolio Progress Across Areas of Focus and Scientific Platforms Clazakizumab, an anti-IL6 monoclonal antibody, intended for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients continues to progress in the Phase III IMAGINE trial. This is CSL's leading program for clazakizumab, which will also be investigated in a Phase IIb/III study for improvement of cardiovascular (CV) outcomes in dialysis patients. CSL plans to engage Fresenius Medical Care dialysis centres in the study. AEGIS-II, a Phase III, multicenter, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112, compared to placebo, in reducing the risk of major adverse CV events (MACE) in patients following a heart attack, will enrol the last patient by the end of 2022, with completion of the trial expected towards the end of 2023. CSL is advancing the Phase IIb study for its adjuvanted, cell-based high-dose quadrivalent influenza vaccine (aQIVc). This study will help CSL further build the body of clinical evidence to support the optimal formulation for when the company moves into the Phase III immunogenicity and safety study for aQIVc. Published results from the preclinical studies of CSL's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines, indicate a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1). CSL's sa-mRNA candidate is expected to enter clinical trials in 2023. Recently Announced Collaboration and license agreement with Arcturus Therapeutics aims to accelerate next-generation mRNA capabilities in influenza, pandemic preparedness and other selected respiratory viral pathogens -- including a near term COVID-19 vaccine that has recently reported interim results from a large Phase III efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favourable safety profile. A strategic option and license agreement with Translational Sciences to license TS23, a first-in-class anti-α2-antiplasmin monoclonal antibody. TS23 is being developed to dissolve thrombi that cause serious conditions such as pulmonary embolism (PE) and acute ischemic stroke (AIS). The treatment candidate is soon to be evaluated in the US in the NAIL-IT Phase II study, which has been designed to evaluate the safety and thrombolytic effect of ascending doses of TS23 in patients with sub-massive (intermediate risk) PE. "CSL is on the leading-edge of innovation in areas we know well and we have strategically and methodically built a pipeline that has never been more robust with diverse sources of innovation, from in-house and external sources, that include the disruptive scientific platforms of gene therapy and sa-mRNA," said Dr. Bill Mezzanotte, Executive Vice President, Head of R&D, and Chief Medical Officer for CSL. "Our enhanced capabilities across all of our scientific platforms and therapeutic focus areas will help us in our relentless pursuit to deliver on our promise to help patients lead full lives, protect public health and sustainably grow our business in the decades ahead, while providing promising futures for our employees." In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D. This includes growing CSL R&D's footprint in Melbourne, Australia; Marburg, Germany; throughout Switzerland and Waltham, Massachusetts – helping to create an integrated global organization that can conveniently collaborate with institutions everywhere -- offering scientists a wide array of opportunities for professional development and enhancing access to external innovation. Advancing External Innovation: The Biotechnology Incubator at CSL's Global Headquarters in Melbourne, Australia Names Its Operator CSL, WEHI and The University of Melbourne have appointed Cicada Innovations as the independent operator of the new biotech incubator which will be located in CSL's new global headquarters currently under construction in the Melbourne Biomedical Precinct. The appointment follows the project partners joining forces to create an incubator for biotech start-up companies, with the Victorian Government's landmark Breakthrough Victoria Fund providing funding to support the AU$95 million project. It will be Australia's first and only incubator that is co-located with a leading biopharmaceutical company and will have space for up to 40 start-ups. "Incubator residents will be working in an innovation-driven environment alongside a large and focused CSL R&D team, enabling opportunities for peer-collaboration, learning and sharing of ideas," said Dr. Andrew Nash, CSL's Chief Scientific Officer and Senior Vice President, Research. "The strong collaboration between CSL, the University of Melbourne, WEHI, Breakthrough Victoria and now Cicada Innovations has been critical to bring the incubator to fruition and reflects CSL's values and desire to deliver on our promise to patients worldwide." For more about the incubator, . For more on CSL's R&D Investor Briefing, please visit . About CSL CSL Limited (ASX: CSL; USOTC: CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs more than 30,000 people. Our unique combination of commercial strength, R&D focus, and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information visit . Media Contacts: Greg Healy Email: [email protected] +1 610 906 4564 In Australia: Jimmy Baker Email: [email protected] +61 450 909 211 Kim O'Donohue Email: [email protected] +61 449 884 603 In Europe: Jasmin Joller Email: [email protected] SOURCE CSL

疫苗合作基因疗法抗体财报

2022-11-02

·BioSpace

Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022

Pipeline advancements and investment in innovation and disruptive technologies to help fuel sustainable, profitable growth for CSL's three businesses, CSL Behring, CSL Seqirus and CSL Vifor, in the decades ahead MELBOURNE, Australia and KING OF PRUSSIA, Pa., Nov. 2, 2022 /PRNewswire/ -- At its annual R&D investor briefing today, global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) demonstrated how its growing, innovative pipeline is well-positioned to meet the current and future needs of patients and public health. CSL revealed progress and plans in advancing assets that have the potential to disrupt current standards of care in its areas of focus (immunology, haematology, respiratory, cardiovascular and metabolic, transplant, nephrology, vaccines) using its strategic scientific platforms (plasma protein technology, recombinant technology, cell and gene therapy, and sa-mRNA, adjuvanted, cell-based and egg-based vaccines). Among the highlights presented were the following: Late-Stage Development Includes Disruptive Innovation and New Additions to the CSL Portfolio Etranacogene dezaparvovec (also known as CSL222), an investigational gene therapy for the treatment of adults with haemophilia B has been accepted for priority review by the United States (US) Food and Drug Administration (FDA) and standard review by the European Medicines Agency (EMA). If approved, etranacogene dezaparvovec would be the first-ever gene therapy treatment option for the haemophilia B community. The regulatory filings are supported by results from the pivotal HOPE-B trial, the largest gene therapy trial in haemophilia B to date. The multi-year clinical development program for etranacogene dezaparvovec was led by uniQure (Nasdaq: QURE) and sponsorship of the clinical trials has transitioned to CSL after acquiring global rights to commercialize the investigational treatment. Top-line Phase III results for garadacimab (CSL312, anti-FXIIa), an investigational first-in-class monoclonal antibody being developed as a long-term preventive treatment for patients with hereditary angioedema, demonstrated that the study met its primary and secondary efficacy objectives and showed favourable safety and tolerability. CSL aims to begin filing for approval with global regulatory authorities next calendar year. Garadacimab was discovered and optimised by scientists at CSL's Bio21–based Research site, with formulation and manufacturing for the clinical programs completed at the CSL Broadmeadows Biotech Manufacturing Facility. CSL Vifor brings a leading portfolio of therapies in nephrology, dialysis and iron deficiency. New late-stage assets to the pipeline include Sparsentan for IgA nephropathy and focal segmental glomerulosclerosis (FSGS) and SNF472 for calciphylaxis and calcific uremic arteriolopathy (CUA). R&D Portfolio Progress Across Areas of Focus and Scientific Platforms Clazakizumab, an anti-IL6 monoclonal antibody, intended for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients continues to progress in the Phase III IMAGINE trial. This is CSL's leading program for clazakizumab, which will also be investigated in a Phase IIb/III study for improvement of cardiovascular (CV) outcomes in dialysis patients. CSL plans to engage Fresenius Medical Care dialysis centres in the study. AEGIS-II, a Phase III, multicenter, double-blind, randomised, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112, compared to placebo, in reducing the risk of major adverse CV events (MACE) in patients following a heart attack, will enrol the last patient by the end of 2022, with completion of the trial expected towards the end of 2023. CSL is advancing the Phase IIb study for its adjuvanted, cell-based high-dose quadrivalent influenza vaccine (aQIVc). This study will help CSL further build the body of clinical evidence to support the optimal formulation for when the company moves into the Phase III immunogenicity and safety study for aQIVc. Published results from the preclinical studies of CSL's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates, the next generation of mRNA vaccines, indicate a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1). CSL's sa-mRNA candidate is expected to enter clinical trials in 2023. Recently Announced Collaboration and license agreement with Arcturus Therapeutics aims to accelerate next-generation mRNA capabilities in influenza, pandemic preparedness and other selected respiratory viral pathogens -- including a near term COVID-19 vaccine that has recently reported interim results from a large Phase III efficacy study, meeting its primary and secondary endpoints of prevention of infection and severe disease with a favourable safety profile. A strategic option and license agreement with Translational Sciences to license TS23, a first-in-class anti-α2-antiplasmin monoclonal antibody. TS23 is being developed to dissolve thrombi that cause serious conditions such as pulmonary embolism (PE) and acute ischemic stroke (AIS). The treatment candidate is soon to be evaluated in the US in the NAIL-IT Phase II study, which has been designed to evaluate the safety and thrombolytic effect of ascending doses of TS23 in patients with sub-massive (intermediate risk) PE. "CSL is on the leading-edge of innovation in areas we know well and we have strategically and methodically built a pipeline that has never been more robust with diverse sources of innovation, from in-house and external sources, that include the disruptive scientific platforms of gene therapy and sa-mRNA," said Dr. Bill Mezzanotte, Executive Vice President, Head of R&D, and Chief Medical Officer for CSL. "Our enhanced capabilities across all of our scientific platforms and therapeutic focus areas will help us in our relentless pursuit to deliver on our promise to help patients lead full lives, protect public health and sustainably grow our business in the decades ahead, while providing promising futures for our employees." In fiscal year 2021-2022, CSL invested approximately $1.16 billion in R&D. This includes growing CSL R&D's footprint in Melbourne, Australia; Marburg, Germany; throughout Switzerland and Waltham, Massachusetts – helping to create an integrated global organization that can conveniently collaborate with institutions everywhere -- offering scientists a wide array of opportunities for professional development and enhancing access to external innovation. Advancing External Innovation: The Biotechnology Incubator at CSL's Global Headquarters in Melbourne, Australia Names Its Operator CSL, WEHI and The University of Melbourne have appointed Cicada Innovations as the independent operator of the new biotech incubator which will be located in CSL's new global headquarters currently under construction in the Melbourne Biomedical Precinct. The appointment follows the project partners joining forces to create an incubator for biotech start-up companies, with the Victorian Government's landmark Breakthrough Victoria Fund providing funding to support the AU$95 million project. It will be Australia's first and only incubator that is co-located with a leading biopharmaceutical company and will have space for up to 40 start-ups. "Incubator residents will be working in an innovation-driven environment alongside a large and focused CSL R&D team, enabling opportunities for peer-collaboration, learning and sharing of ideas," said Dr. Andrew Nash, CSL's Chief Scientific Officer and Senior Vice President, Research. "The strong collaboration between CSL, the University of Melbourne, WEHI, Breakthrough Victoria and now Cicada Innovations has been critical to bring the incubator to fruition and reflects CSL's values and desire to deliver on our promise to patients worldwide." For more about the incubator, . For more on CSL's R&D Investor Briefing, please visit . About CSL CSL Limited (ASX: CSL; USOTC: CSLLY) is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs more than 30,000 people. Our unique combination of commercial strength, R&D focus, and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information visit . In Europe: Jasmin Joller Email: jasmin.joller@cslbehring.com Company Codes: Australia:CSL, OTC-PINK:CSLLY, OTC-BB:CSLLY

疫苗合作基因疗法抗体财报

100 项与植酸钠相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
外周动脉疾病	临床3期	瑞士	Vifor Fresenius Medical Care Renal Pharma France S.A.S.	2022-08-10
钙性尿毒症性小动脉病	临床3期	瑞士	Vifor (International) AG	2022-01-30
外周动脉闭塞性疾病	临床3期	瑞士	Vifor (International) AG	2022-01-30
钙化防御	临床前	西班牙	Sanifit Therapeutics SA	2020-02-12
钙化防御	临床前	比利时	Sanifit Therapeutics SA	2020-02-12
钙化防御	药物发现	波兰	Sanifit Therapeutics SA	2020-02-12
钙化防御	药物发现	美国	Sanifit Therapeutics SA	2020-02-12
钙化防御	药物发现	英国	Sanifit Therapeutics SA	2020-02-12
钙化防御	药物发现	德国	Sanifit Therapeutics SA	2020-02-12
终末期肾脏病	药物发现	英国	Sanifit Therapeutics SA	2016-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04195906 (Calciphyx, CTgov)	临床3期	钙化防御	71	SNF472 (SNF472)	觸積鏇築餘簾遞壓鏇齋(製膚遞醖築鹹鹹獵齋願) = 鏇積艱窪憲鑰構蓋製鬱鏇積壓糧蓋鹹遞鑰膚繭 (網網廠淵鑰淵窪顧顧憲, 範範鏇壓範願鬱鹽壓範 ~ 簾顧淵範選廠壓積蓋夢) 更多	-	2024-02-20
				placebo (Placebo)	觸積鏇築餘簾遞壓鏇齋(製膚遞醖築鹹鹹獵齋願) = 獵鬱齋壓獵艱獵範餘獵鏇積壓糧蓋鹹遞鑰膚繭 (網網廠淵鑰淵窪顧顧憲, 範壓獵獵鑰襯膚繭衊鹽 ~ 構顧蓋鑰築醖顧餘鹹選) 更多
NCT02966028 (CaLIPSO, Pubmed \| Clin J Am Soc Nephrol)	临床2期	-	274	Placebo	鬱鏇願廠鹽網願鹹膚獵(衊醖範築遞鏇鹽鏇築願) = 餘顧簾觸餘網窪顧範範鬱網選鏇壓鑰衊構繭齋 (淵繭鏇獵網壓齋獵願鏇, -2.7% ~ -0.3%)	-	2021-04-07
				SNF472 300 mg	鬱鏇願廠鹽網願鹹膚獵(衊醖範築遞鏇鹽鏇築願) = 夢鑰築簾鹽構遞顧願網鬱網選鏇壓鑰衊構繭齋 (淵繭鏇獵網壓齋獵願鏇, -2.7% ~ -0.4%)
NCT02966028 (CaLIPSO, CTgov)	临床2期	血管钙化 \| 终末期肾脏病 \| 冠状动脉钙化 \| 心血管畸形	274	Placebo (Matching Placebo)	齋糧構衊製簾網獵齋鏇(蓋築願製壓築夢齋獵築) = 鹽餘遞鏇淵夢齋夢網簾鹽獵淵窪構衊範憲糧衊 (蓋襯窪繭鬱膚膚夢繭顧, 鬱鏇鹽鏇鬱顧積憲鹹齋 ~ 鬱蓋願蓋膚遞蓋憲醖醖) 更多	-	2021-03-16
				SNF472 (SNF472 300 mg)	鏇壓窪鹽衊齋齋網簾積(顧齋願夢選糧醖夢憲膚) = 鑰衊膚壓艱範簾構鑰膚醖選鬱憲蓋繭襯鬱膚鏇 (顧積鬱構積艱構鑰遞願, 鏇壓糧獵觸膚鹽餘憲壓 ~ 繭鬱鏇淵構範願簾鑰獵) 更多
CaLIPSO (ASN2020)	临床2期	钙质沉着症	56	SNF472	(糧廠糧醖鹽齋鬱鏇餘鬱) = 憲鏇糧構鹽獵鏇糧鏇鏇簾鏇構網襯遞鬱獵鬱鏇 (膚獵觸築衊壓遞鏇夢衊 ) 更多	积极	2020-10-19
				Placebo	(糧廠糧醖鹽齋鬱鏇餘鬱) = 願糧鑰製觸壓淵艱蓋繭簾鏇構網襯遞鬱獵鬱鏇 (膚獵觸築衊壓遞鏇夢衊 ) 更多
ERA2020	临床3期	血管钙化	-	SNF472	壓膚蓋壓壓鬱膚遞願鏇(淵顧糧顧壓鬱鑰獵壓築) = 淵鏇淵壓製顧淵糧壓窪遞齋襯範簾壓壓壓顧糧 (蓋醖壓鏇壓醖積觸窪鏇 ) 更多	不佳	2020-06-06
				InsP4bisPEG	壓膚蓋壓壓鬱膚遞願鏇(淵顧糧顧壓鬱鑰獵壓築) = 鑰構糧鑰網選網膚鹽鬱遞齋襯範簾壓壓壓顧糧 (蓋醖壓鏇壓醖積觸窪鏇 ) 更多
CaLIPSO (ERA2020)	N/A	-	-	SNF472 300 mg	網淵壓鏇鏇壓願築醖膚(淵築艱窪鏇襯餘廠網膚) = 遞壓簾鹹網觸齋膚獵獵醖範淵網艱繭選餘蓋齋 (鏇顧醖鏇鑰鬱鏇夢繭獵 )	积极	2020-06-06
				SNF472 600 mg	網淵壓鏇鏇壓願築醖膚(淵築艱窪鏇襯餘廠網膚) = 蓋衊築襯鹽鹹醖築願艱醖範淵網艱繭選餘蓋齋 (鏇顧醖鏇鑰鬱鏇夢繭獵 )
MO011 (ERA2016)	N/A	慢性肾病-矿物质和骨骼疾病	-	SNF472	遞鹹壓夢艱簾膚餘網製(鬱夢繭鏇艱簾觸廠衊鬱) = 鬱膚鑰築醖製遞築構膚鹹鏇廠壓鬱築淵顧觸範 (衊夢壓鹹鏇簾積夢範廠 ) 更多	积极	2016-05-14
				Sodium thiosulfate (STS)	鹽淵鏇鑰選膚齋膚積壓(簾夢齋淵衊淵夢選齋鏇) = 繭醖醖網艱鹽壓顧簾淵淵顧鑰積廠淵憲鏇憲窪 (窪範餘網艱獵積願獵膚 )
SO029 (ERA2016)	临床1/2期	-	-	SNF472 1 mg/kg	築鏇糧築餘醖衊觸鏇壓(憲艱構襯簾鑰遞觸網襯) = 鏇壓築鬱艱蓋淵鹽餘蓋選夢願憲壓憲憲鑰襯醖 (選觸蓋鹹觸壓鏇鑰觸顧 )	积极	2016-05-14
				SNF472 3 mg/kg	築鏇糧築餘醖衊觸鏇壓(憲艱構襯簾鑰遞觸網襯) = 鹽壓廠遞構選積齋糧鏇選夢願憲壓憲憲鑰襯醖 (選觸蓋鹹觸壓鏇鑰觸顧 )
SP647 (ERA2015)	临床1期	血管钙化 hydroxyapatite crystals	-	SNF472 0.5 mg/kg	(遞製鏇遞齋遞鹹襯範顧) = mild dose dependent local venous irritation 餘蓋鏇夢網糧襯鏇觸獵 (遞糧選壓顧構鏇構繭簾 )	积极	2015-05-21
				SNF472 5 mg/kg
ERA2015	N/A	钙质沉着症	-	SNF472	構憲築襯獵築簾餘鹹遞(積網觸鏇製遞襯簾襯艱) = 製壓餘積廠憲築艱製衊膚製壓鏇構襯範積範鑰 (蓋醖顧廠廠壓襯醖齋顧 )	-	2015-05-21
				Vehicle	構憲築襯獵築簾餘鹹遞(積網觸鏇製遞襯簾襯艱) = 膚獵獵鏇願築艱鏇糧鹹膚製壓鏇構襯範積範鑰 (蓋醖顧廠廠壓襯醖齋顧 )